Verrica Pharmaceuticals Management
Management criteria checks 1/4
Verrica Pharmaceuticals' CEO is Jayson Rieger, appointed in Nov 2024, has a tenure of less than a year. total yearly compensation is $1.50M, comprised of 3.2% salary and 96.8% bonuses, including company stock and options. directly owns 0.96% of the company’s shares, worth $551.73K. The average tenure of the management team and the board of directors is 0.5 years and 7 years respectively.
Key information
Jayson Rieger
Chief executive officer
US$1.5m
Total compensation
| CEO salary percentage | 3.19% |
| CEO tenure | less than a year |
| CEO ownership | 1.0% |
| Management average tenure | less than a year |
| Board average tenure | 7yrs |
Recent management updates
Recent updates
Turnaround Plan Will Commercialize YCANTH And Advance Pipeline
Cost reductions and focus on YCANTH commercialization could improve future revenues and net margins, aiding the turnaround plan.The Price Is Right For Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Even After Diving 49%
Oct 03
Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Analysts Are Cutting Their Estimates: Here's What You Need To Know
Aug 17With A 67% Price Drop For Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) You'll Still Get What You Pay For
Aug 16Is Verrica Pharmaceuticals (NASDAQ:VRCA) Using Debt In A Risky Way?
Jul 21Is Verrica Pharmaceuticals (NASDAQ:VRCA) Using Debt In A Risky Way?
Jan 11Here's Why We're Not At All Concerned With Verrica Pharmaceuticals' (NASDAQ:VRCA) Cash Burn Situation
Jun 28We're Hopeful That Verrica Pharmaceuticals (NASDAQ:VRCA) Will Use Its Cash Wisely
Feb 05Vectoring Back In On Verrica Pharmaceuticals
Aug 31Verrica Pharmaceuticals reports insider buying
Jul 06Verrica Pharmaceuticals stock slides on proposed share offering
Jun 29CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Mar 31 2025 | n/a | n/a | -US$66m |
| Dec 31 2024 | US$1m | US$48k | -US$77m |
Compensation vs Market: Jayson's total compensation ($USD1.50M) is above average for companies of similar size in the US market ($USD645.80K).
Compensation vs Earnings: Insufficient data to compare Jayson's compensation with company performance.
CEO
Jayson Rieger (48 yo)
Dr. Jayson M. Rieger, Ph D., M.B.A., is President, CEO & Director of Verrica Pharmaceuticals Inc. from November 5, 2024. Dr. Rieger served as Non-Executive Independent Director at Lytix Biopharma AS since...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | less than a year | US$1.50m | 0.96% $ 551.7k | |
| Interim Chief Financial Officer | less than a year | no data | no data | |
| Chief Operating Officer | less than a year | no data | 0.12% $ 68.2k | |
| Executive Vice President of Technical Operations | 5.6yrs | no data | no data | |
| Head of Drug Development | 4.8yrs | no data | no data | |
| Chief Medical Officer | less than a year | no data | no data |
Experienced Management: VRCA's management team is not considered experienced ( 0.5 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 9.4yrs | US$1.50m | 0.96% $ 551.7k | |
| Independent Director | 7yrs | US$201.90k | 0% $ 0 | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Independent Director | 4.8yrs | US$191.90k | 0% $ 0 | |
| Director | 9.4yrs | no data | 2.03% $ 1.2m | |
| Independent Director | less than a year | no data | 0.000020% $ 11.5 | |
| Chairman of the Board | 9.4yrs | no data | 58.07% $ 33.3m | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Independent Director | 4.9yrs | US$171.90k | 0.00011% $ 63.1 | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data |
Experienced Board: VRCA's board of directors are considered experienced (7 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/23 09:10 |
| End of Day Share Price | 2025/05/23 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Verrica Pharmaceuticals Inc. is covered by 12 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jason Matthew Gerberry | BofA Global Research |
| Brian Kemp Dolliver | Brookline Capital Markets |
| Oren Livnat | H.C. Wainwright & Co. |